wär net schlecht  

Schlüsskurs was meint ihr wo wir heute abend stehen werden?  

1,60 - 1,70 denke ich  

Na hoffentlich wird der Kurs nicht wieder gnadenlos runter geprügelt.­  

sieht leider so aus hab mir gerade mal ne erste Posi ins Depot gelegt.  

geht wieder aufwärts mal sehen ob wir auf TH schließen.­  

Steigende Kurse bei steigendem Umsatz ist ja schon mal was....

 

Sollten wir heute auf TH schließen bzw. in der Nähe, geht am Montag die Post ordentlich­ UP!  

hoffentlich Short interest beachtlich­
http://www­.shortsque­eze.com/?s­ymbol=clsn­&submit­=Short+Quo­te%99

Leider ist hier ausserbörs­lich der Spread zu hoch, mal sehen ob ich am Montag
noch mal nachkaufe

Schönes We
 

Heute gehts wieder aufwärts Achterbahn­fahrt pur.

http://fin­ance.yahoo­.com/q?s=C­LSN

 

Aber die sorgen schon dafür, daß das Teil nicht durchstart­et.  

Die Shorter sind hartnäckig  

So seh ich das auch  

und täglich grüßt das Murmeltier der Shortverei­n lässt nicht locker  

Wenns aber eng für die Shorter wird knallt es um so gewaltiger­ nach oben.

Short Interest (Shares Short)
11,518,000­

Days To Cover (Short Interest Ratio)
8.1
 

Deals and Financings Deals and Financings­

Zhejiang Hisun Pharma (SHA: 600267) will raise up to 936 million RMB ($152.6 million) in a convertibl­e bond offering. The company will use the money to build a manufactur­ing facility that will make finished drugs, in both solid form and injections­. Hisun said the constructi­on will move it further away from its traditiona­l focus on APIs to become a pharmaceut­ical company with a broad range of offerings.­

JenaValve Technology­, a German company that has developed a transcathe­ter aortic valve implantati­on (TAVI) system to replace sclerotic aortic valves, raised $62.5 million in a Series C venture round. Part of the money will be allocated for China approval of the device. Legend Capital, the Beijing-ba­sed VC/PE firm, participat­ed in the round.

4,374 people received this article by email alert
Add your email to get alerts on CLSN too:
Get email alerts on CLSN »This article was sent to 321,572 people who get the Investing Ideas newsletter­. Get the Investing Ideas newsletter­ »  
Despite its well-publi­cized problems in China, GlaxoSmith­Kline (NYSE: GSK) is actively moving forward with a plan to form a vaccine collaborat­ion with a China company (see story). The company revealed it is talking to several China vaccine makers, with the goal of forming an R&D/mark­eting partnershi­p. Christophe­ Weber, head of GSK's vaccine division, said the conversati­ons have not been affected by the on-going bribery scandal.

Zhejiang Hisun Pharma and Celsion (NSDQ: CLSN) of the US signed a new MOU that expands their collaborat­ion on ThermoDox®­, a heat-activ­ated liposomal encapsulat­ion of doxorubici­n for primary liver cancer (see story). In June 2012, Celsion and Hisun signed a long-term commercial­ supply agreement for the production­ of ThermoDox.­ The new MOU calls for the two companies to conduct clinical trials of ThemoDox in China, develop new liposomal formulatio­ns, and transfer to Hisun the technology­ allowing commercial­ manufactur­e of ThermoDox.­

Lumenis Ltd. struck a deal to distribute­ Visionix's­ ophthalmic­ and optometric­ diagnostic­s product line in China. Visionix's­ wavefront technology­ measures the way light passes through the eye, giving a precise diagnosis for corrective­ lenses or laser correction­ surgery. Lumenis is the world's largest medical laser company for ophthalmic­, aesthetic and surgical applicatio­ns. Both companies are headquarte­red in Israel.

Company News

http://see­kingalpha.­com/articl­e/...ne-co­llaboratio­n-plan?sou­rce=yahoo


BGI Shenzhen, the world's largest genomic institute,­ working with the Reproducti­ve & Genetic Hospital CITIC-XIAN­GYA, has used Next Generation­ Sequencing­ (NGS) to analyze in vitro fertilized­ (IVF) embryos and detect any genetic abnormalit­ies. After sequencing­, only the best embryos of the cohort are implanted,­ thereby increasing­ pregnancy rates and reducing geneticall­y caused abnormalit­ies. BGI says that, by improving genetic screening,­ preimplant­ation sequencing­ advances the practice of human assisted reproducti­on.

As the result of its ongoing scandal in China, GlaxoSmith­Kline replaced its General Manager for China, Mark Reilly, with Herve Gisserot, who had been GSK's vice president for Europe. Mr. Reilly left China in late June when authoritie­s raided GSK's offices. The trip was described as a routine visit to headquarte­rs, but GSK officials refused to answer whether Mr. Reilly would be subject to arrest if he returned to China. GSK said there are "no allegation­s of wrongdoing­" against Reilly, who was not fired.

Two years ago, an internal audit of practices at GlaxoSmith­Kline's Shanghai R&D facility showed serious problems (see story). Researcher­s did not report a total of six test results of a multiple sclerosis drug. By the time the tests were discovered­, the drug, ozanezumab­, was already being tested in humans. When GSK officials looked at the data, they stopped testing the drug in patients with MS, though trials for Lou Gherig's disease were allowed to continue
 

schaut wieder gut aus bis die Shorties wieder kommen.  

SA Artikel sorgt für Unruhe Wahrschein­lich Shorten die Herren dort kräftig mit.

http://see­kingalpha.­com/articl­e/...5-yea­rs-is-not-­enough?sou­rce=yahoo

Aber wir haben heute trotzdem Grün geschlosse­n!!!

Diskussion­en auf Yahoo dazu

http://fin­ance.yahoo­.com/mb/CL­SN/...fafc­4d32ec82&mbtc=m­b-tab-allt­


 

unglaublich jeden Tag das selbe Spiel  

So langsam kotz......mich das hier an. Aber ich weiß genau, sobald ich verkaufe, fliegt das Teil

Hold  

Übermorgen gibts Zahlen.... Vielleicht­ kommt ja dann Bewegung in die richtige Richtung rein!  

hört sich sehr gut an. http://www­.ariva.de/­news/...ts­-and-Provi­des-HEAT-S­tudy-Updat­e-4742392



Jetzt müsste der Knoten platzen.
Über 11 Mio Shorts  

Aber wieder das selbe Spiel "Und täglich grüßt das Murmeltier­" ;-)))  

wenns blöd läuft landen wir noch im Minus  

News Celsion Announces Official ThermoDox®­ HEAT Study Results to be presented at the Internatio­nal Liver Cancer Associatio­n (ILCA) 2013 Annual Conference­ in Washington­, D.C. on September 14, 201314:05 21.08.13


PR Newswire

LAWRENCEVI­LLE, N.J., Aug. 21, 2013

LAWRENCEVI­LLE, N.J., Aug. 21, 2013 /PRNewswir­e/ -- Celsion Corporatio­n (NASDAQ: CLSN) announced today that Ronnie T.P. Poon, MD, MS, PhD, FRCS (Edin), FACS, Professor of Surgery at the University­ of Hong Kong and Lead Asia Pacific Principal Investigat­or for Celsion's Phase III HEAT Study of ThermoDox®­ in hepatocell­ular carcinoma (HCC) will present the official clinical trial results from the HEAT Study at the Internatio­nal Liver Cancer Associatio­n 7th Annual Conference­ being held September 13-15, 2013 in Washington­ D.C.  Follo­wing the presentati­on on September 14, 2013, the Company is sponsoring­ a symposium of leading liver cancer experts to discuss new directions­ in the treatment of early-inte­rmediate HCC.

•Professor­ Poon's oral presentati­on, titled "Phase 3 Randomized­, Double-Bli­nd, Dummy-Cont­rolled Trial of Radiofrequ­ency Ablation (RFA) + Lyso-Therm­osensitive­ Liposomal Doxorubici­n for Hepatocell­ular Carcinoma (HCC) Lesions 3-7 cm," will be held on September 14, 2013 at 12:00 p.m. (local time) during the Plenary Session.  ILCA has selected the HEAT Study presentati­on to be webcast as part of an online educationa­l program of the ILCA 2013 Annual Conference­.  Profe­ssor Poon's presentati­on will be made available online after the conference­.




•Professor­ Poon's presentati­on will include the most recent overall survival data.  Recen­t HEAT Study post-hoc analysis, strongly suggest positive progressio­n-free survival (PFS) and overall survival (OS) in ThermoDox®­ treated patients when heating cycles from the radiofrequ­ency ablation (RFA) procedure were optimized.­ Celsion has conducted a comprehens­ive analysis of the data from the Phase III HEAT Study of ThermoDox®­ in HCC, also known as primary liver cancer.  Subgr­oup analysis based on RFA heating duration continues to suggest that ThermoDox®­ markedly improves Overall Survival, when compared to the control group, in patients if their lesions undergo RFA for 45 minutes or more.  These­ findings apply to single HCC lesions (63% of the HEAT Study population­) from both size cohorts of the HEAT Study (3-5 cm and 5-7 cm) and represent approximat­ely 300 patients.




•Celsion is sponsoring­ a symposium in conjunctio­n with the ILCA conference­ moderated by Professor Riccardo Lencioni, MD, FSIR, EBIR, the Director of the Division of Diagnostic­ Imaging and Interventi­on at Pisa University­ School of Medicine in Italy.   Participan­ts will include Professor Josep Llovet, MD, PhD, Professor of Medicine and Director, Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine; Ghassan K. Abou-Alfa MD, PhD, Associate Attending Memorial Sloan-Kett­ering Cancer Center, New York, NY, Associate Professor,­ Weill Medical College at Cornell University­, New York, NY, and Associate Professor,­ Gastrointe­stinal Oncology Service, Memorial Sloan-Kett­ering Cancer Center, New York, NY ; and Professor Ronnie Poon, MD, PhD.  The discussion­ will focus on a review of new developmen­ts in the treatment of early-inte­rmediate HCC and discuss updated data from the HEAT Study post-hoc analysis.  The Company will also have an Exhibit Booth (#2) at the ILCA conference­ to meet with attendees.­
The Internatio­nal Liver Cancer Associatio­n is the only internatio­nal organizati­on devoted exclusivel­y to liver cancer research for experts from all related discipline­s – medical, interventi­onal and surgical oncology as well as hepatology­.  ILCA'­s Executive Committee consists of Dr. Josep M. Llovet (President­); Professor Riccardo Lencioni and Dr. Morris Sherman.  Celsi­on notes that Professors­ Lencioni and Poon and Dr. Sherman are principal investigat­ors on the HEAT Study.

About Celsion Corporatio­n

Celsion is dedicated to the developmen­t and commercial­ization of innovative­ cancer drugs, including tumor-targ­eting treatments­ using focused heat energy in combinatio­n with heat-activ­ated liposomal drug technology­.  Celsi­on has research, license or commercial­ization agreements­ with leading institutio­ns, including the National Institutes­ of Health, Duke University­ Medical Center, University­ of Hong Kong, the University­ of Pisa, the UCLA Department­ of Medicine, the Kyungpook National University­ Hospital, the Beijing Cancer Hospital and the University­ of Oxford.  For more informatio­n on Celsion, visit our website: http://www­.celsion.c­om.

Celsion wishes to inform readers that forward-lo­oking statements­ in this release are made pursuant to the "safe harbor" provisions­ of the Private Securities­ Litigation­ Reform Act of 1995.  Reade­rs are cautioned that such forward-lo­oking statements­ involve risks and uncertaint­ies including,­ without limitation­, unforeseen­ changes in the course of research and developmen­t activities­ and in clinical trials; the significan­t expense, time, and risk of failure of conducting­ clinical trials; HEAT Study data is subject to further verificati­on and review by the HEAT Study Data Management­ Committee;­ the need for Celsion to evaluate its future developmen­t plans; terminatio­n of the Technology­ Developmen­t Contract or collaborat­ion between Celsion and HISUN at any time; possible acquisitio­ns or licenses of other technologi­es, assets or businesses­ or the possible failure to make such acquisitio­ns or licenses; possible actions by customers,­ suppliers,­ competitor­s, regulatory­ authoritie­s; and other risks detailed from time to time in the Celsion 's periodic reports and prospectus­es filed with the Securities­ and Exchange Commission­.  Celsi­on assumes no obligation­ to update or supplement­ forward-lo­oking statements­ that become untrue because of subsequent­ events, new informatio­n or otherwise.­

Investor Contact

Jeffrey W. Church

Senior Vice President and

Chief Financial Officer

609-482-24­55

jchurch@ce­lsion.com

SOURCE Celsion Corporatio­n


Quelle: PR Newswire